Jaguar Health, Inc.
JAGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $12 | $10 | $12 | $4 |
| % Growth | 19.8% | -18.4% | 175.8% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $2 |
| Gross Profit | $10 | $8 | $10 | $2 |
| % Margin | 83.3% | 79.1% | 83.1% | 46.2% |
| R&D Expenses | $17 | $19 | $18 | $15 |
| G&A Expenses | $16 | $17 | $18 | $17 |
| SG&A Expenses | $24 | $23 | $27 | $26 |
| Sales & Mktg Exp. | $8 | $6 | $9 | $9 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $41 | $42 | $44 | $43 |
| Operating Income | -$31 | -$34 | -$34 | -$41 |
| % Margin | -263.8% | -351.3% | -287.8% | -939.1% |
| Other Income/Exp. Net | -$8 | -$8 | -$14 | -$12 |
| Pre-Tax Income | -$39 | -$42 | -$48 | -$53 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38 | -$41 | -$47 | -$53 |
| % Margin | -329.3% | -423.1% | -396.9% | -1,213.3% |
| EPS | -130.69 | -2,685 | -4,070,250 | -11,370,375 |
| % Growth | 95.1% | 99.9% | 64.2% | – |
| EPS Diluted | -130.69 | -2,685 | -4,070,250 | -11,370,375 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $8 |
| Interest Expense | $0 | $6 | $13 | $8 |
| Depreciation & Amortization | $2 | $1 | $2 | $2 |
| EBITDA | -$37 | -$33 | -$33 | -$42 |
| % Margin | -313.6% | -335.6% | -279.2% | -977.3% |